Head-to-head · Cost-Efficiency Index
OnlyRx vs NexLife
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
OnlyRx
Shoppers who want a 50-state marketplace with multiple pharmacy options and named prescribers.
Visit OnlyRxNexLife
Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Visit NexLifeThe verdict
OnlyRx takes it, leading the Cost-Efficiency Index 64 to 63. OnlyRx is a 50-state GLP-1 telehealth marketplace offering compounded semaglutide (injection or oral/ODT) and tirzepatide (injection or oral/ODT). NexLife still earns a C — Cost-first shoppers who want wanting a genuinely flat, dose-independent price and willing to prepay a multi-month term for the lowest advertised rate.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs OnlyRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | OnlyRx | NexLife |
|---|---|---|
| Cost-Efficiency Index | 64/100 | 63/100 |
| Semaglutide / mo | $179/mo (starting dose, compounded) | $165/mo (all doses, compounded) |
| Tirzepatide / mo | $249/mo (starting dose, compounded) | $215/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $2,148 | $1,980 |
| Tirzepatide / yr (modeled) | $2,988 | $2,580 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #180 | #185 |
OnlyRx
64/100Where the value is
- Serves all 50 states per its own claim, wider than most compounded-GLP-1 competitors
- Two named prescribers with published NPI numbers (Dr. Ana Lisa Carr, Dr. Kelly Tenbrink), plus two supporting providers
- Sources medication from four named, recognizable 503A-style pharmacy partners rather than one undisclosed source
The tradeoffs
- The $179 headline price is explicitly labeled a 'Summer Promo' on the site's own homepage — no post-promo price is published
- No dose-tier (mg) breakdown is published for any of the four price points
NexLife
63/100Where the value is
- Flat pricing confirmed at every dose for both drugs — no per-mg escalation during titration, unlike most compounded competitors in this batch
- LegitScript certified with a named medical director (Adam Kennah, M.D.)
- States every batch undergoes independent third-party testing for potency, sterility, pH, and endotoxin levels
The tradeoffs
- The commonly advertised '$186/mo' tirzepatide headline requires a 12-month commitment; the true no-commitment month-to-month price is $215/mo — about 16% more
- No individual compounding pharmacy is named, only 'LegitScript-certified, NABP-accredited' pharmacies generically
Regulatory note: the FDA issued a warning letter to Nexlife Inc. dba Nexlife in June 2026. We still list and link to NexLife; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.